Please use this identifier to cite or link to this item:
|Title:||Emerging treatments for major depression.||Austin Authors:||Norman, Trevor R ;Burrows, Graham D||Affiliation:||University of Melbourne, Department of Psychiatry, Austin Hospital, Heidelberg 3084, Victoria, Australia||Issue Date:||1-Feb-2007||Publication information:||Expert Review of Neurotherapeutics; 7(2): 203-13||Abstract:||Antidepressant drugs were introduced into clinical practice in the mid-20th Century. While for the most part they have proven effective for the amelioration of depressive symptoms, they are associated with significant deficiencies. These well-recognized shortcomings have given impetus to the pursuit of new molecules that seek to improve on the efficacy, tolerability and safety of existing medications. The following article reviews several new compounds that may have antidepressant potential. Some are more advanced in development, having undergone clinical trials, whereas the clinical potential of others is yet to be explored. For this latter group of compounds, the antidepressant potential relies on their activity in validated animal models. Agomelatine and duloxetine are in the first category, having shown antidepressant efficacy in clinical trials. The blockade of cortisol secretion continues to be a focus of attention for the development of new antidepressants. Thus, synthesis inhibitors, nonpeptide antagonists of corticotropin-releasing factor and glucocorticoid receptor antagonists show some promise in clinical and preclinical tests. Antagonists of the neuropeptide substance P, vasopressin and neuropeptide Y represent a departure of approach from traditional monoamine receptor-based mechanisms. While the clinical results with one substance P antagonist have led to the cessation of further trials, other molecules are in development. Approaches to treatment based on glutamatergic transmission arose from observations in animal models. The clinical evaluation of such compounds awaits further development. The extent to which new agents can be judged to have met the goals of efficacy, tolerability and safety rely not only acute treatment trials but also on longer-term outcomes and postmarketing surveillance. Whether any of the new agents canvassed here prove to be significantly better than existing agents is clearly a judgement for the future.||Gov't Doc #:||17286553||URI:||http://ahro.austin.org.au/austinjspui/handle/1/10317||DOI:||10.1586/14737188.8.131.52||URL:||https://pubmed.ncbi.nlm.nih.gov/17286553||Type:||Journal Article||Subjects:||Animals
Antidepressive Agents.therapeutic use
Depressive Disorder, Major.drug therapy
|Appears in Collections:||Journal articles|
Show full item record
checked on Nov 29, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.